Aurora Cannabis to Graduate to TSX

Visit the Aurora Cannabis Investor Dashboard and stay up to date with data-driven, fact based due diligence for active traders and investors.

VANCOUVER, July 10, 2017 /CNW/ – Aurora Cannabis Inc. (the “Company” or “Aurora”) (TSXV: ACB) (OTCQX: ACBFF) (Frankfurt: 21P; WKN: A1C4WM) announced today that the Company has received conditional approval from the Toronto Stock Exchange (the “TSX”) to graduate from the TSX Venture Exchange and list its common shares on the TSX. Upon receiving final approval, the common shares will continue to trade under the symbol “ACB”. In conjunction with listing on the TSX, the common shares will be voluntarily delisted from the TSX Venture Exchange prior to the commencement of trading on the TSX.

“Aurora’s graduation to the TSX, for which we anticipate receiving final approval imminently, is another exciting milestone, reflecting our remarkable pace of growth and expansion, both across Canada and internationally,” said Terry Booth, CEO. “Since we began commercial operations 18 months ago, Aurora has established itself as a driving force, with one of the strongest brands in the cannabis industry, due to constant innovation and consistent execution. Tangible developments, such as the construction of Aurora Sky, our 100,000 kg per year cannabis production facility, the acquisitions in Québec and Germany, as well as our strategic investments in Cann Group in Australia, and Radient Technologies in Alberta, reflect how Aurora continues to set new standards in the industry.”

Having uplisted from the CSE to the TSXV in October, 2016, we believe that now graduating to the TSX will enable us to address an even wider investor audience, both domestically and internationally. We remain focused strongly on building shareholder value, and look forward to reporting on our progress as a member of Canada’s flagship stock exchange.

Terry Booth, CEO

About Aurora

Aurora’s wholly-owned subsidiary, Aurora Cannabis Enterprises Inc., is a licensed producer of medical cannabis pursuant to Health Canada’s Access to Cannabis for Medical Purposes Regulations (“ACMPR”). The Company operates a 55,200 square foot, state-of-the-art production facility in Mountain View County, Alberta, and is currently constructing a second 800,000 square foot production facility, known as “Aurora Sky”, at the Edmonton International Airport, and has acquired, and is undertaking completion of, a third 40,000 square foot production facility in Pointe-Claire, Quebec, on Montreal’s West Island. In addition, the company is the cornerstone investor with a 19.9% stake in Cann Group Limited, the first Australian company licensed to conduct research on and cultivate medical cannabis, as well as owns Pedanios, a leading wholesale importer, exporter, and distributor of medical cannabis in the European Union (“EU”), based in Germany. Aurora’s common shares trade on the TSX-V under the symbol “ACB”.

Orginal press release:

The most reliable, fact-based information on Aurora Cannabis found only on its Investor Dashboard.

Before this cannabis stock news is here, it’s published to subscribers on 420 Investor.

Published by NCV Newswire
NCV Newswire
The NCV Newswire by New Cannabis Ventures aims to curate high quality content and information about leading cannabis companies to help our readers filter out the noise and to stay on top of the most important cannabis business news. The NCV Newswire is hand-curated by an editor and not automated in anyway. For questions contact us.

Get Our Sunday Newsletter